Consistent with this notion, CRISPR-mediated inversion of −31CBS disrupts an existing TAL1 promoter/enhancer interaction and inhibits TAL1 expression in T-ALL cells leading to interfering leukemia progression. The gene discussed is TAL1; the disease is leukemia.